Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent advances of IDH1 mutant inhibitor in cancer therapy

24 Aug 2022

Abstract excerpt

Isocitrate dehydrogenase (IDH) is the key metabolic enzyme that catalyzes the conversion of isocitrate to α-ketoglutarate (α-KG). Two main types of IDH1 and IDH2 are present in humans. In recent years, mutations in IDH have been observed in several tumors, including glioma, acute myeloid leukemia, and chondrosarcoma. Among them, the frequency of IDH1 mutations is higher than IDH2. IDH1 mutations have been shown...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Epigenetics and DNA Methylation
Share to Glioma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36091829
DOI: 10.3389/fphar.2022.982424

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent advances of IDH1 mutant inhibitor in cancer therapyPMID 36091829Read ↗

Development of Novel Therapeutics Targeting Isocitrate Dehydrogenase Mutations in Cancer.Semantic proximity Read ↗

The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.Semantic proximity Read ↗

The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.Semantic proximity Read ↗

IDH mutations in cancer and progress toward development of targeted therapeutics.Semantic proximity Read ↗

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia.Semantic proximity Read ↗

Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer TherapeuticsSemantic proximity Read ↗

Biological Roles and Therapeutic Applications of IDH2 Mutations in Human CancerSemantic proximity Read ↗

The regulatory mechanisms and inhibitors of isocitrate dehydrogenase 1 in cancerSemantic proximity Read ↗

IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.Semantic proximity Read ↗

Challenges for the development of mutant isocitrate dehydrogenases 1 inhibitors to treat glioma.Semantic proximity Read ↗

Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia: Emerging Options and Pending QuestionsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.